Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BW85
UPID:
YJU2_HUMAN
Alternative names:
Coiled-coil domain-containing protein 94
Alternative UPACC:
Q9BW85; O75270; Q9H862; Q9NW16
Background:
Splicing factor YJU2, also known as Coiled-coil domain-containing protein 94, is integral to the spliceosome, facilitating precise mRNA splicing by catalyzing transesterification reactions. This process is crucial for generating mature mRNA from pre-mRNA, involving the removal of non-coding introns and the joining of coding exons. YJU2 enhances the spliceosome's catalytic core stability and aids in the docking process, essential for accurate mRNA synthesis.
Therapeutic significance:
Understanding the role of Splicing factor YJU2 could open doors to potential therapeutic strategies. Its involvement in mRNA splicing and cell protection from TP53-dependent apoptosis upon DNA damage highlights its potential as a target in diseases where these processes are dysregulated.